Yan Ma

Yan Ma

Auto-generated profile, based on publicly available information

Yan Ma

Department of Radiation Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2023 in Cancer Medicine
Verified
Journal Article
Open access
MCMo Chen
Mo Chen
YMYan Ma
Yan Ma
YSYi‐Wen Song
Yi‐Wen Song
JHJinhua Huang
Jinhua Huang
YGYuan‐Hong Gao
Yuan‐Hong Gao
FHFang He
Fang He
Purpose: MRI‐detected extramural venous invasion (mrEMVI) is associated with poor survival outcomes in patients with locally advanced rectal cancer (LARC). An mrEMVI‐positive status is considered a strong indication for neoadjuvant treatment, but the optimal regimen is unknown.Patients and Methods: We retrospectively compared pathological and survival outcomes of 584 patients diagnosed with mrEMVI‐positive rectal cancer between January 2013 and October 2021, and receiving either neoadjuvant chemotherapy (NCT) alone, neoadjuvant chemoradiotherapy (nCRT) alone, or nCRT plus NCT, prior to total mesorectal excision. Propensity score matching (PSM) was used to balance clinical bias between groups, which were compared using chi‐square testing and Kaplan–Meier curves.Results: Median follow‐up was 33.9 (range, 10.2–100.4) months. The 3‐year overall survival (OS), disease‐free survival (DFS), distant metastasis‐free survival (DMFS), and locoregional relapse‐free survival (LRFS) rates for all patients were 90.4%, 57.5%, 61.1%, and 85.7%, respectively. Of 584 mrEMVI‐positive patients at the time of diagnosis, 457 (78.3%) were EMVI‐negative on surgical pathology, and they had significantly better 3‐year OS, DMFS, DFS, and LRFS rates (all p < 0.001) than patients who remained EMVI‐positive. After PSM was applied, patients receiving nCRT alone had significantly better 3‐year OS (96.8% vs. 86.5%, p = 0.005) and DMFS (67.1% vs. 53.5%, p = 0.03) rates than those receiving NCT alone. Patients receiving NCT plus nCRT had higher pathological complete response (PCR) (10.8% vs. 2.7%, p = 0.04) and downstaging (33.8% vs. 5.3%, p < 0.001) rates than those receiving nCRT alone, but survival rates did not differ (all p > 0.05).Conclusion: Most EMVI‐positive patients with LARC converted to EMVI‐negative after neoadjuvant treatment, resulting in improved OS and DFS. Patients receiving nCRT had more favorable survival outcomes than those receiving NCT, suggesting the importance of including neoadjuvant radiotherapy. Patients receiving NCT in addition to nCRT had higher rates of PCR and downstaging, but their survival rates were not better.

1 January 2019 in Cancer Control
Verified
Journal Article
Open access
PDF file
XFXinjuan Fan
Xinjuan Fan
YXYa Xie
Ya Xie
HCHaiyang Chen
Haiyang Chen
XGXiaobo Guo
Xiaobo Guo
YMYan Ma
Yan Ma
JZJian Zheng
Jian Zheng
Identifying metastasis remains a challenge for death control and tailored therapy for nasopharyngeal carcinoma (NPC). Here, we addressed this by designing a nomogram-based Cox proportional regression model through integrating a panel of tumor biomarkers. A total of 147 locally patients with advanced NPC, derived from a randomized phase III clinical trial, were enrolled. We constructed the model by selecting the variables from 31 tumor biomarkers, including 6 pathological signaling pathway molecules and 3 Epstein-Barr virus-related serological variables. Through the least absolute shrinkage and selection operator (LASSO) Cox proportional regression analysis, a nomogram was designed to refine the metastasis risk of each NPC individuals. Using the LASSO Cox regression model, we constructed a 9 biomarkers-based prognostic nomogram: Beclin 1, Aurora-A, Cyclin D1, Ki-67, P27, Bcl-2, MMP-9, 14-3-3σ, and VCA-IgA. The time-dependence receiver operating characteristic analysis at 1, 3, and 5 years showed an appealing prognostic accuracy with the area under the curve of 0.830, 0.827, and 0.817, respectively. In the validation subset, the concordance index of this nomogram reached to 0.64 to identify the individual metastasis pattern. Supporting by this nomogram algorithm, the individual metastasis risk might be refined personally and potentially guiding the treatment decisions and target therapy against the related signaling pathways for patients with locally advanced NPC.

17 May 2025 in Advances in Radiation Oncology
Verified
Journal Article
Open access
YMYan Ma
Yan Ma
HCHai-Yang Chen
Hai-Yang Chen
FHFu-Jing Huang
Fu-Jing Huang
XPXiao-Lin Pang
Xiao-Lin Pang
JZJian Zheng
Jian Zheng
FHFang He
Fang He
This study aimed to evaluate the efficacy and safety of volumetric-modulated arc therapy (VMAT) in treating corticosteroid-resistant orbital inflammatory diseases, with a focus on radiation therapy (RT) plan design, clinical outcomes, and the incidence of treatment-related side effects. A retrospective analysis was conducted on 57 patients with refractory, corticosteroid-resistant orbital inflammatory diseases treated with orbital VMAT from November 2019 to July 2022. The primary endpoint was the reduction or cessation of corticosteroid use following RT, with secondary endpoints, including improvements in ocular clinical symptoms (diplopia, proptosis, visual acuity, and extraocular movement) and long-term side effects. The median target dose was 20 Gy, with an average lens irradiation dose of 5.4 Gy. Initially, all 57 patients received corticosteroids. After a median follow-up of 27.5 months, 89.5% (51 of 57) of patients responded positively to RT; in particular, 56.1% (32 of 57) completely tapered off corticosteroids, whereas 33.3% (19 of 57) reduced their dosage. Symptomatic improvements were observed in diplopia (67.3%), proptosis (64.7%), visual acuity (56.1%), and extraocular movements (65.9%). Regarding the long-term side effects of RT, incidences of dry eye syndrome and lens opacities were reported at 3.5% and 1.8%, respectively. Orbital VMAT is an effective treatment for refractory, corticosteroid-resistant orbital inflammatory diseases, reducing corticosteroid use and improving ocular symptoms with minimal side effects. Further prospective clinical trials are warranted to validate more appropriate VMAT doses and planning models, enhancing treatment outcomes without increasing RT side effects.